

Key Figures (IFRS)

MorphoSys Group (in million €, if not stated otherwise)

	12/31/14	12/31/13	12/31/12	12/31/11	12/31/10	12/31/09	12/31/08	12/31/07	12/31/06	12/31/05
RESULTS¹										
Revenues	64.0	78.0	51.9	82.1	87.0	81.0	71.6	62.0	53.0	33.5
Cost of Goods Sold	0.0	0.0	0.0	0.0	7.3	6.7	7.1	7.9	8.0	2.5
R&D Expenses	56.0	49.2	37.7	55.9	46.9	39.0	27.6	22.2	17.5	14.0
S, G&A Expenses	14.1	18.8	12.1	14.9	23.2	23.9	20.5	24.8	21.4	10.8
Personnel Expenses (Excluding Stock-Based Compensation)	26.7	27.4	24.1	27.7	29.6	26.1	21.5	18.8	18.1	10.8
Capital Expenditure	20.5	5.6	1.8	2.9	13.8	3.8	3.8	12.0	4.0	0.7
Depreciation of Tangible Assets	1.4	1.5	1.7	1.7	2.1	1.6	1.5	1.5	1.5	0.9
Amortization of Intangible Assets	2.7	3.3	3.5	3.8	4.0	3.8	4.8	3.7	3.4	2.7
EBITDA	2.4	16.4	7.9	15.5	19.2	18.1	21.9	13.3	10.3	8.6
EBIT	(5.9)	9.9	2.5	9.8	13.1	12.8	16.5	8.3	5.4	5.3
Net Profit/(Loss)	(3.0)	13.3	1.9	8.2	9.2	9.0	13.2	11.5	6.0	4.7
Net Profit/(Loss) from Discontinued Operations	0.0	6.0	(0.4)	0.0	-	-	-	-	-	-
BALANCE SHEET										
Total Assets	426.5	447.7	224.3	228.4	209.8	206.1	203.3	184.7	127.8	80.1
Cash, Marketable Securities and Other Financial Assets	352.8	390.7	135.7	134.4	108.4	135.1	137.9	106.9	66.0	53.6
Intangible Assets	46.0	35.1	35.0	66.0	69.2	17.4	19.7	22.3	14.8	12.4
Total Liabilities	77.7	95.5	22.3	31.3	23.9	32.2	41.3	39.2	27.8	16.1
Stockholders' Equity	348.8	352.1	202.0	197.1	185.9	173.9	162.0	145.5	100.1	64.0
Equity Ratio (in %)	82%	79%	90%	86%	89%	84%	80%	79%	78%	80%
MORPHOSYS SHARE										
Number of Shares Issued	26,456,834	26,220,882	23,358,228	23,112,167	22,890,252	22,660,557	22,478,787	22,160,259	20,145,966	18,077,589
Group Earnings/(Loss) per Share, Diluted (in €)	(0.12)	0.54	0.08	0.36	0.4	0.4	0.59	0.53	0.31	0.28
Dividend (in €)	-	-	-	-	-	-	-	-	-	-
Share Price (in €)	76.63	55.85	29.3	17.53	18.53	17.04	18.75	16.1	18.12	13.77
PERSONNEL DATA										
Total Group Employees (Number ²)	329	299	421	446	464	404	334	295	279	172

¹ Due to the agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the AbD Serotec segment, for the years 2013, 2012 and 2011, revenues, income and expenses in connection with the transaction are shown in the line item "Net Profit/(Loss) from Discontinued Operations." All other line items consist of amounts from continuing operations.

² 2005 to 2012 including employees from the discontinued operations of AbD Serotec.